Degarelix dosage in published studies and labels

These are the doses used for Degarelix in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.

Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.

Last checked against primary sources: November 7, 2026

Studied regimens and sources

Degarelix has an FDA-approved human dosage for advanced prostate cancer. The FIRMAGON label gives a 240 mg starting dose as two 120 mg injections under the skin of the abdomen, then 80 mg as one injection every 28 days, starting 28 days after the first dose.

FDA Approved

Dosage evidence summary for Degarelix
Human dosing established	Yes
Route	Subcutaneous
Frequency	Starting dose once, then every 28 days
Duration studied	Long-term
Evidence level	FDA Approved
Last reviewed	2026-11-07

Research-reported dosing

Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.

Research-reported dosing for Degarelix, one row per studied regimen
Study / context	Population	Dose	Route	Frequency	Duration	Outcome studied	Source
FDA label — FIRMAGON, advanced prostate cancerFDA-approved label · FDA prescribing information	Patients with advanced prostate cancer	Starting dose 240 mg as two 120 mg injections (40 mg/mL); maintenance 80 mg as one injection (20 mg/mL)	Subcutaneous, abdomen only	Maintenance every 28 days, the first 28 days after the starting dose	Long-term	Treatment of advanced prostate cancer	FIRMAGON (degarelix for injection) — FDA prescribing information (Ferring), DailyMed
CS21 — phase 3 trial against leuprolide (Klotz et al., 2008)Clinical trial · Phase 3 randomised open-label trial	Men with prostate adenocarcinoma needing androgen deprivation (n=610)	240 mg start, then 80 mg or 160 mg monthly; comparator leuprolide 7.5 mg intramuscularly monthly	Subcutaneous	Monthly	12 months	Testosterone at or below 0.5 ng/mL from day 28 to day 364 in 97.2% (240/80 mg), 98.3% (240/160 mg) and 96.4% (leuprolide); injection-site reactions 40% with degarelix against under 1% with leuprolide	Klotz L et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008.

Where sources disagree

The starting and maintenance doses use different concentrations (40 mg/mL and 20 mg/mL). The label says FIRMAGON is given by a healthcare professional only.
The label warns of hypersensitivity reactions including anaphylaxis, QT interval prolongation with androgen deprivation therapy, and embryo-fetal toxicity.
In the CS21 trial testosterone was at or below 0.5 ng/mL 3 days after the first dose in about 96% of men on degarelix and in none on leuprolide. FIRMAGON is labelled as a GnRH receptor antagonist; leuprolide, the comparator, is a GnRH agonist.